Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 473742, 10 pages
http://dx.doi.org/10.1155/2015/473742
Research Article

Krüppel-Like Factor 4 Inhibits the Transforming Growth Factor-β1-Promoted Epithelial-to-Mesenchymal Transition via Downregulating Plasminogen Activator Inhibitor-1 in Lung Epithelial Cells

Division of Respiratory Disease, Renmin Hospital of Wuhan University, Wuhan 430060, China

Received 22 August 2015; Revised 1 November 2015; Accepted 10 November 2015

Academic Editor: Ralf Lichtinghagen

Copyright © 2015 Fang Sun and Ke Hu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Selman, T. E. King Jr., and A. Pardo, “Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy,” Annals of Internal Medicine, vol. 134, no. 2, pp. 136–151, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. K. O. Leslie, “Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis,” Archives of Pathology and Laboratory Medicine, vol. 136, no. 6, pp. 591–600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Warburton, “Developmental responses to lung injury: repair or fibrosis,” Fibrogenesis and Tissue Repair, vol. 5, no. 1, article S2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Warburton, W. Shi, and B. Xu, “TGF-β-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development?” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 304, no. 2, pp. L83–L85, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Zhao, W. Shi, Y.-L. Wang et al., “Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 282, no. 3, pp. L585–L593, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. B. B. McConnell and V. W. Yang, “Mammalian Krüppel-like factors in health and diseases,” Physiological Reviews, vol. 90, no. 4, pp. 1337–1381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Zhou, W. L. Hofstetter, Y. He et al., “KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression,” Cancer Biology and Therapy, vol. 9, no. 7, pp. 507–513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Zhang, J. Zhang, Z. W. Wang, L. Zha, and Z. Huang, “Altered expression of krüppel-like factor 4 and β-catenin in human gastric cancer,” Oncology Letters, vol. 3, no. 5, pp. 1017–1022, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S. H. Shin, Y. W. Kwon, S. C. Heo et al., “Kröppel-like factor 4 mediates lysophosphatidic acid-stimulated migration and proliferation of PC3M prostate cancer cells,” Experimental and Molecular Medicine, vol. 46, no. 7, article e104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Zhang, H. Zhu, Y. Wang et al., “Krüppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines,” Biological Chemistry, vol. 390, no. 5-6, pp. 463–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. N. V. Patel, A. M. Ghaleb, M. O. Nandan, and V. W. Yang, “Expression of the tumor suppressor Krüppel-like factor 4 as a prognostic predictor for colon cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 10, pp. 2631–2638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Tiwari, N. Meyer-Schaller, P. Arnold et al., “Klf4 is a transcriptional regulator of genes critical for EMT, including Jnk1 (Mapk8),” PLoS ONE, vol. 8, no. 2, Article ID e57329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Cui, M. Shi, M. Quan, and K. Xie, “Regulation of EMT by KLF4 in gastrointestinal cancer,” Current Cancer Drug Targets, vol. 13, no. 9, pp. 986–995, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Xiao, W. Tang, Q. Yuan, L. Peng, and P. Yu, “Epigenetic repression of Krüppel-like factor 4 through Dnmt1 contributes to EMT in renal fibrosis,” International Journal of Molecular Medicine, vol. 35, pp. 1596–1602, 2015. View at Publisher · View at Google Scholar
  15. Z.-S. Lin, H.-C. Chu, Y.-C. Yen, B. C. Lewis, and Y.-W. Chen, “Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression,” PLoS ONE, vol. 7, no. 8, Article ID e43593, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Moreno-Bueno, E. Cubillo, D. Sarrió et al., “Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition,” Cancer Research, vol. 66, no. 19, pp. 9543–9556, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. E. Wilkins-Port, C. E. Higgins, J. Freytag, S. P. Higgins, J. A. Carlson, and P. J. Higgins, “PAI-1 is a critical upstream regulator of the TGF-β1/EGF-induced invasive phenotype in mutant p53 human cutaneous squamous cell carcinoma,” Journal of Biomedicine and Biotechnology, vol. 2007, Article ID 85208, 8 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. B. V. Offersen, B. S. Nielsen, G. Høyer-Hansen et al., “The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas,” American Journal of Pathology, vol. 163, no. 5, pp. 1887–1899, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Illemann, U. Hansen, H. J. Nielsen et al., “Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1,” American Journal of Clinical Pathology, vol. 122, no. 2, pp. 256–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Dennler, S. Itoh, D. Vivien, P. ten Dijke, S. Huet, and J.-M. Gauthier, “Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitortype 1 gene,” The EMBO Journal, vol. 17, no. 11, pp. 3091–3100, 1998. View at Publisher · View at Google Scholar
  21. L. R. Lund, A. Riccio, P. A. Andreasen et al., “Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts,” EMBO Journal, vol. 6, no. 5, pp. 1281–1286, 1987. View at Google Scholar · View at Scopus
  22. J. A. Hamilton, G. A. Whitty, J. Wojta, M. Gallichio, K. McGrath, and G. Ianches, “Regulation of plasminogen activator inhibitor-1 levels in human monocytes,” Cellular Immunology, vol. 152, no. 1, pp. 7–17, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Kimura, X. Li, K. Torii et al., “Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells,” Clinical and Experimental Nephrology, vol. 15, no. 1, pp. 34–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Ma, J. S. Ryu, A. Dulay, M. Segal, and S. Guller, “Regulation of plasminogen activator inhibitor (PAI)-1 expression in a human trophoblast cell line by glucocorticoid (GC) and transforming growth factor (TGF)-β,” Placenta, vol. 23, no. 10, pp. 727–734, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Wickert, N. Chatain, K. Kruschinsky, and A. M. Gressner, “Glucocorticoids activate TGF-β induced PAI-1 and CTGF expression in rat hepatocytes,” Comparative Hepatology, vol. 6, article 5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. T. H. Sisson and R. H. Simon, “The plasminogen activation system in lung disease,” Current Drug Targets, vol. 8, no. 9, pp. 1016–1029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. T. Eitzman, R. D. McCoy, X. Zheng et al., “Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene,” The Journal of Clinical Investigation, vol. 97, no. 1, pp. 232–237, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Hattori, J. L. Degen, T. H. Sisson et al., “Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice,” Journal of Clinical Investigation, vol. 106, no. 11, pp. 1341–1350, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Senoo, N. Hattori, T. Tanimoto et al., “Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis,” Thorax, vol. 65, no. 4, pp. 334–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Tanjore, X. C. Xu, V. V. Polosukhin et al., “Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 7, pp. 657–665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Tanjore, X. C. Xu, V. V. Polosukhin et al., “Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 7, pp. 657–665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. K. K. Kim, M. C. Kugler, P. J. Wolters et al., “Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13180–13185, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. K. K. Kim, Y. Wei, C. Szekeres et al., “Epithelial cell α3β1 integrin links β-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis,” The Journal of Clinical Investigation, vol. 119, no. 1, pp. 213–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. B. C. Willis and Z. Borok, “TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 293, no. 3, pp. L525–L534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Huang and C. J. Elferink, “A novel nonconsensus xenobiotic response element capable of mediating aryl hydrocarbon receptor-dependent gene expression,” Molecular Pharmacology, vol. 81, no. 3, pp. 338–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S. R. Wilson, A. D. Joshi, and C. J. Elferink, “The tumor suppressor kruppel-like factor 6 is a novel aryl hydrocarbon receptor DNA binding partner,” Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 3, pp. 419–429, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Hamik, Z. Lin, A. Kumar et al., “Kruppel-like factor 4 regulates endothelial inflammation,” Journal of Biological Chemistry, vol. 282, no. 18, pp. 13769–13779, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. Boon, J. O. Fledderus, O. L. Volger et al., “KLF2 suppresses TGF-beta signaling in endothelium through induction of Smad7 and inhibition of AP-1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 532–539, 2007. View at Publisher · View at Google Scholar · View at Scopus